Lab
Sanford Clinic North
Sanford Clinic North was paid $7.02M by Medicaid between Jan 2018 and Jul 2024, across 154 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 15% of everything it billed.
33Billing provider infoSANFORD CLINIC NORTH
FARGO, ND 58122
FARGO, ND 58122
33aNPI1225194574assigned 12/29/2006
33bProvider typeClinical Medical Laboratory
28Total paid$7.02M
24GClaims397,327
24DCodes billed154
24AFirst – last monthJan 2018 – Jul 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in North Dakota
Rank by total paid#2 of 15
Median peer was paid$4K
This provider vs. median1,734×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,288 | $451K | |
| 2019 | 71,732 | $1.74M | |
| 2020 | 66,566 | $1.61M | |
| 2021 | 73,516 | $1.22M | |
| 2022 | 51,451 | $701K | |
| 2023 | 61,879 | $775K | |
| 2024incomplete | 37,895 | $524K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 15% | 22,874 | 14,152 | $1.03M |
| 80053 | Comprehensive metabolic panel | 7.8% | 23,240 | 19,970 | $549K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 6.4% | 6,148 | 5,407 | $448K |
| 88307 | 4.7% | 2,208 | 1,864 | $332K | |
| 84443 | Thyroid stimulating hormone (TSH) | 4.5% | 23,390 | 21,996 | $318K |
| 88342 | 3.8% | 3,576 | 2,692 | $269K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.8% | 8,369 | 7,858 | $268K |
| 80050 | General health panel | 3.5% | 2,572 | 2,381 | $246K |
| 80061 | Lipid panel | 3.2% | 14,016 | 12,980 | $224K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 2.7% | 6,489 | 6,112 | $187K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.4% | 1,703 | 1,537 | $170K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 20,923 | 16,668 | $147K |
142 more codes
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.9% | 3,486 | $136K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.9% | 6,151 | $132K |
| 36415 | Collection of venous blood by venipuncture | 1.8% | 51,594 | $124K |
| 82728 | 1.8% | 9,969 | $123K | |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 8,803 | $112K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.3% | 1,700 | $94K |
| 83013 | 1.3% | 861 | $88K | |
| 82607 | 1.2% | 5,519 | $86K | |
| 86780 | 1.2% | 7,321 | $83K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.1% | 10,122 | $80K |
| 86803 | 1.1% | 6,002 | $79K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 1.1% | 5,813 | $78K |
| 83970 | <1% | 1,126 | $66K | |
| 88341 | <1% | 1,370 | $66K | |
| 86480 | <1% | 694 | $63K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,399 | $61K |
| 83550 | <1% | 8,555 | $52K | |
| 88304 | <1% | 2,791 | $51K | |
| 87077 | <1% | 4,910 | $51K | |
| 82784 | <1% | 3,563 | $49K | |
| 84702 | <1% | 3,345 | $48K | |
| 87186 | <1% | 4,581 | $42K | |
| 86481 | <1% | 281 | $40K | |
| 87150 | <1% | 1,384 | $39K | |
| 87340 | <1% | 4,822 | $39K | |
| 83540 | <1% | 8,841 | $39K | |
| 80076 | <1% | 1,688 | $37K | |
| 86850 | <1% | 3,128 | $33K | |
| 84165 | <1% | 2,897 | $32K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 1,131 | $31K |
| 86140 | <1% | 7,086 | $31K | |
| 84439 | <1% | 4,938 | $29K | |
| 84481 | <1% | 1,069 | $28K | |
| 82043 | <1% | 4,086 | $27K | |
| 80069 | <1% | 1,518 | $27K | |
| 87070 | <1% | 2,504 | $27K | |
| 82570 | <1% | 6,768 | $25K | |
| 83880 | <1% | 481 | $25K | |
| 86038 | <1% | 1,649 | $21K | |
| 84146 | <1% | 905 | $21K | |
| 83735 | <1% | 3,998 | $20K | |
| 87507 | <1% | 64 | $20K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 137 | $19K |
| 82746 | <1% | 854 | $18K | |
| 86160 | <1% | 633 | $18K | |
| 88108 | <1% | 756 | $16K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 224 | $16K |
| 86762 | <1% | 845 | $15K | |
| 85610 | <1% | 3,382 | $15K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 195 | $15K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 529 | $14K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 76 | $13K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 224 | $12K |
| 85027 | <1% | 2,138 | $12K | |
| 81001 | <1% | 3,293 | $12K | |
| 87210 | <1% | 1,874 | $11K | |
| 87522 | Neg quan hep c or qual rna | <1% | 101 | $11K |
| 88300 | <1% | 1,272 | $10K | |
| 84403 | <1% | 324 | $10K | |
| 88141 | <1% | 420 | $9K | |
| 80074 | <1% | 89 | $8K | |
| 86900 | <1% | 3,047 | $7K | |
| 86706 | <1% | 1,007 | $7K | |
| 87634 | <1% | 118 | $7K | |
| 82950 | <1% | 1,597 | $7K | |
| 86901 | <1% | 2,895 | $7K | |
| 83001 | <1% | 416 | $7K | |
| 84156 | <1% | 2,021 | $6K | |
| 84460 | <1% | 1,024 | $6K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 178 | $6K |
| 88312 | <1% | 100 | $6K | |
| 82077 | <1% | 52 | $6K | |
| 83615 | <1% | 1,328 | $6K | |
| 85652 | <1% | 2,818 | $6K | |
| 0240U | <1% | 45 | $6K | |
| 84153 | <1% | 346 | $6K | |
| 82565 | <1% | 959 | $5K | |
| 86431 | <1% | 733 | $5K | |
| 86334 | <1% | 334 | $5K | |
| 84100 | <1% | 1,273 | $5K | |
| 81025 | <1% | 603 | $5K | |
| 81003 | <1% | 2,057 | $5K | |
| 87088 | <1% | 764 | $5K | |
| G0124 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician | <1% | 146 | $4K |
| 81015 | <1% | 1,423 | $4K | |
| 82550 | <1% | 645 | $4K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 71 | $4K |
| 36416 | <1% | 792 | $4K | |
| 83690 | <1% | 779 | $4K | |
| 87205 | <1% | 1,079 | $3K | |
| 84703 | <1% | 277 | $3K | |
| 80177 | <1% | 239 | $3K | |
| 80164 | <1% | 244 | $3K | |
| 83516 | <1% | 141 | $3K | |
| 86704 | <1% | 286 | $2K | |
| 84550 | <1% | 749 | $2K | |
| 86592 | <1% | 560 | $2K | |
| 82274 | <1% | 83 | $2K | |
| 80081 | <1% | 25 | $2K | |
| 84450 | <1% | 562 | $2K | |
| 84484 | <1% | 211 | $2K | |
| 87529 | <1% | 41 | $2K | |
| 83002 | <1% | 120 | $2K | |
| 87631 | <1% | 14 | $2K | |
| 88302 | <1% | 118 | $2K | |
| 82670 | <1% | 75 | $2K | |
| 87040 | <1% | 107 | $1K | |
| 85046 | <1% | 376 | $1K | |
| 85246 | <1% | 58 | $1K | |
| 88311 | <1% | 255 | $1K | |
| 88313 | <1% | 60 | $1K | |
| 85245 | <1% | 45 | $1K | |
| 85240 | <1% | 56 | $1K | |
| 85730 | <1% | 251 | $984.97 | |
| 80178 | <1% | 137 | $872.65 | |
| 85018 | <1% | 484 | $848.02 | |
| 82947 | <1% | 218 | $808.77 | |
| 85379 | <1% | 102 | $783.43 | |
| G0141 | Screening cytopathology smears, cervical or vaginal, performed by automated system, with manual rescreening, requiring interpretation by physician | <1% | 34 | $750.72 |
| 87493 | <1% | 24 | $716.44 | |
| 86696 | <1% | 13 | $616.11 | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 53 | $587.87 |
| 82533 | <1% | 53 | $582.49 | |
| 80197 | <1% | 65 | $571.18 | |
| 82150 | <1% | 129 | $514.29 | |
| 82627 | <1% | 26 | $513.30 | |
| 86361 | <1% | 25 | $511.88 | |
| 85007 | <1% | 162 | $496.09 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 15 | $351.16 |
| 84132 | <1% | 35 | $316.22 | |
| 88188 | <1% | 15 | $260.32 | |
| 83993 | <1% | 12 | $215.93 | |
| 82105 | <1% | 12 | $197.35 | |
| 82140 | <1% | 26 | $145.70 | |
| 86364 | <1% | 12 | $110.69 | |
| 86695 | <1% | 13 | $65.95 | |
| 82977 | <1% | 12 | $54.89 | |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 145 | $50.08 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 36 | $38.61 |
| 90686 | <1% | 40 | $27.72 | |
| 86308 | <1% | 14 | $23.94 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLECLERC, MARTHA (VICE PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Perham Hospital District | Perham, MN | $2.05M |
| Sanford Clinic North | Fargo, ND | $4K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.